Prevalence of hepatitis B and C virus infection in haematological malignancies and liver injury following chemotherapy

European Journal of Haematology

Volumn 74, Issue 2, 2005, Pages 158-165

  Takai, Shinji ^a   Tsurumi, Hisashi ^a   Ando, Kazuki ^a   Kasahara, Senji ^b   Sawada, Michio ^a   Yamada, Toshiki ^a   Hara, Takeshi ^a   Fukuno, Kenji ^c   Takahashi, Takeshi ^d   Oyama, Masami ^b   Onishi, Hiroo ^e   Tomita, Eiichi ^a   Takami, Tsuyoshi ^d   Imawari, Michio ^f   Moriwaki, Hisataka ^a  

^a GIFU UNIVERSITY SCHOOL OF MEDICINE   (Japan)

^b GIFU UNIVERSITY   (Japan)

^c Takayama Red Cross Hospital   (Japan)

^d Gifu Municipal Hospital   (Japan)

^e GIFU PREFECTURAL GIFU HOSPITAL   (Japan)

^f SHOWA UNIVERSITY SCHOOL OF MEDICINE   (Japan)

Author keywords

Chemotherapy; Hepatitis virus; Lamivudine; Non Hodgkin's lymphoma

Indexed keywords

ASPARAGINASE; CYCLOPHOSPHAMIDE; DAUNORUBICIN; DEXAMETHASONE; DOXORUBICIN; ENOCITABINE; ETOPOSIDE; LAMIVUDINE; MELPHALAN; MERCAPTOPURINE; METHOTREXATE; MITOXANTRONE; PIRARUBICIN; PREDNISOLONE; RANIMUSTINE; STEROID; VINCRISTINE; VINDESINE;

ACUTE LEUKEMIA; ADULT; AGED; ARTICLE; CANCER CHEMOTHERAPY; CONTROLLED STUDY; FEMALE; HEMATOLOGIC MALIGNANCY; HEPATITIS B; HEPATITIS B VIRUS; HEPATITIS C; HEPATITIS C VIRUS; HUMAN; INFECTION RISK; JAPAN; LIVER INJURY; MAJOR CLINICAL STUDY; MALE; MULTIPLE MYELOMA; NONHODGKIN LYMPHOMA; POPULATION RESEARCH; PREVALENCE; PRIORITY JOURNAL; STEROID THERAPY; T CELL LEUKEMIA; VIRUS CARRIER;

ADOLESCENT; ADULT; AGED; AGED, 80 AND OVER; ANTINEOPLASTIC AGENTS; CARRIER STATE; FEMALE; HEMATOLOGIC NEOPLASMS; HEPATITIS B; HEPATITIS B VIRUS; HEPATITIS C; HUMANS; JAPAN; LAMIVUDINE; LIVER; MALE; MIDDLE AGED; PREVALENCE; REVERSE TRANSCRIPTASE INHIBITORS; VIRUS ACTIVATION;

EID: 19944432285     PISSN: 09024441     EISSN: None     Source Type: Journal    
DOI: 10.1111/j.1600-0609.2004.00376.x     Document Type: Article

References (35)

1. Japan Red Cross. Report of the research group for prophylaxis of post-transfusion hepatitis (editorial). 1996;7-14.
2. LAU JYN, LAI CL, LIN HJ, LOK ASF, LIANG RHS, WU PC, CHAN TK. TODD D. Fatal reactivation of chronic hepatitis following withdrawal of chemotherapy in lymphoma patients. Q J Med 1989;73:911-917.
3. LIANG RHS, LOK ASF, LAI CL, CHAN TK, TODD D, CHIU EKW. Hepatitis B infection in patients with lymphomas. Hematol Oncol 1990;8:261-270.
4. LOK ASF, LIANG RHS, CHIU EKW, WONG KL, CHAN TK, TODD D. Reactivation of hepatitis B virus replication in patients receiving cytotoxic therapy. Report of a prospective study. Gastroenterology 1991;100:182-188.
5. NAKAMURA Y, MOTOKURA T, FUJITA A, YOSHITA T, OGATA E. Severe hepatitis related to chemotherapy in hepatitis B virus carriers with hematologic malignancies. Cancer 1996;78:2210-2215.
6. KUMAGAI K, TAKAGI T, NAKAMURA S, et al. Hepatitis B virus carriers in the treatment of malignant lymphoma: an epidemiological study in Japan. Ann Oncol 1997;8:107-109.
7. SILVESTRI F, ERMACORA A, SPEROTTO A, PATRIARCA F, ZAJA F, DAMIANI D, FANIN R, BACCARANI M. Lamivudine allows completion of chemotherapy in lymphoma patients with hepatitis B reactivation. Br J Haematol 2000;108:394-396.
8. LIAO CA, LEE CM, WU HC, WANG MC, LU SN, ENG HL. Lamivudine for the treatment of hepatitis B virus reactivation following chemotherapy for non-Hodgkin's lymphoma. Br J Haematol 2002;116:166-169.
9. SHIBOLET O, IIAN Y, GILLIS S, HUBERT A, SHOUVAL D, SARADI R. Lamivudine therapy for prevention of immunosuppressive-induced hepatitis B virus reactivation in hepatitis B surface antigen carriers. Blood 2002;100:391-396.
10. ROSSI G, PELIZZARI A, MOTTA M, PUOTI M. Primary prophylaxis with lamivudine of hepatitis B virus reactivation in chronic HbsAg carriers with lymphoid malignancies treated with chemotherapy. Br J Haematol 2001;115:58-62.
11. MIYAWAKI S, TANIMOTO M, KOBAYASHI T, MINAMI S, TAMURA J, OMOTO E, KURIYAMA K, HATAKE K, SAITO K, OHNO R. Effect of etoposide added to individualized induction therapy of adult acute myeloid leukemia: the JALSG-AML92 Study. Japan Adult Leukemia Study Group. Gan To Kagaku Ryoho 2000;27:1160-1167.
12. UEDA T, MIYAWAKI S, Asou N, et al. Response-oriented individualized induction therapy with six drug followed by four courses of intensive consolidation, 1 year maintenance and intensification therapy: the ALL 90 study of the Japan Adult Leukemia Study Group. Int J Hematol 1998;68:279-289.
13. TSURUMI H, YAMADA T, SAWADA M, et al. Biweekly CHOP/biweekly THP-COP regimen in the treatment of aggressive non-Hodgkin's lymphoma - comparison of doxorubicin and pirarubicin: a randomized phase II study. J Cancer Res Clin Oncol 2004;130:107-113.
14. FISHER RI, GAYNOR ER, DAHLBERG S, OKEN MM, GROGAN TM, MIZE EM, GLICK JH, COLTMAN CA, Jr, MILLER TP. Comparison of a standard regimen (CHOP) with three intensive chemotherapy regimens for advanced non-Hodgkin's lymphoma. N Engl J Med 1993;328:1002-1006.
15. TAGUCHI H, KINOSHITA KI, TAKATSUKI K, et al. An intensive chemotherapy of adult T-cell leukemia/lymphoma: CHOP followed by etoposide, vindesine, ranimustine, and mitoxantrone with granulocyte colony-stimulating factor support. J Acquir Immune Defic Syndr 1996;12:182-186.
16. GREGORY WM, RICHARDS MA, MALPAS JS. Combination chemotherapy versus melphalan and prednisolone in the treatment of multiple myeloma: an overview of published trials. J Clin Oncol 1992;10:334-342.
17. ALEXIANIAN R, BARLOGIE B, DIXON D. High-dose glucocorticoid treatment of resistant myeloma. Ann Intern Med 1986;105:887-890.
18. CUCUIANU A, PATIU M, DUMA M, BASARAB C, SORITAU O, BOJAN A, VASILACHE A, MATES M, PETROV L. Hepatitis B and C virus infection in Romanian non- Hodgkin's lymphoma patients. Br J Haematol 1999;107:353-356.
19. KUNIYOSHI M, NAKAMUTA M, SAKAI H, et al. Prevalence of hepatitis B or C virus infections in patients with non-Hodgkin's lymphoma. J Gastroenterol Hepatol 2001;16:215-219.
20. NEGRI E, LITTLE D, BOIOCCHI M, VECCHIA CA, FRANCESCHI S. B-cell non-Hodgkin's lymphoma and hepatitis C virus infection: a systematic review. Int J Cancer 2004;111:1-8.
21. KASPA R, BURK RD, SHAUL Y, SHAFRITZ DA. Hepatitis B virus DNA contains a glucocorticoid-responsive element. Proc Natl Acad Sci USA 1986;83:1627-1631.
22. LAM KC, LAI CL, TREPO C, WU PC. Deleterious effect of prednisolone in HbsAg-positive chronic active hepatitis. N Engl J Med 1981;304:380-386.
23. CHENG AL. Steroid free chemotherapy decreases the risk of hepatitis flare ups in hepatitis B virus carriers with non-Hodgkin's lymphoma. Blood 1996;87:1202.
24. CHENG AL, HSIUNG CA, SU IJ, et al. Steroid free chemotherapy decreases risk of hepatitis B virus (HBV) reactivation in HBV-carriers with lymphoma. Hepatology 2003;37:1320-1328.
25. DOONG SL, TSAI CH, SCHINAZI RF, LIOTTA DC, CHENG YC. Inhibition of the replication of hepatitis B virus in vitro by 2′,3′-dideoxy-3′- thiacytidine and related analogues. Proc Natl Acad Sci USA 1991;88:8495-8499.
26. DIESTAG JL, PERRILLO RP, SCHIFF ER, BARTHOLOMEW M, VICARY C, RUBIN M. A preliminary trial of lamivudine for chronic hepatitis B infection. N Engl J Med 1995;333:1657-1661.
27. NEVENS F, MAIN J, HONKOOP P, TYRRELL DL, BARBAR J, SULLIVAN M, FEVERY J, DE MAN RA, THOMAS HC. Lamivudine therapy for chronic hepatitis B: a six-month randomized dose-ranging study. Gastroenterology 1997;113:1258-1263.
28. LAI CL, CHEIN RN, LEUNG NWY, et al. A one-year trial of lamivudine for chronic hepatitis B. N Engl J Med 1998;339:61-68.
29. CENRY A, CHISARI FV. Pathogenesis of chronic hepatitis C: immunological features of hepatic injury and viral persistence. Hepatology 1999;30:595-601.
30. MARKOVIC S, DROZINA G, VOVK M, FIDLER-JENKO M. Reactivation of hepatitis B but not hepatitis C in patients with malignant lymphoma and immunosuppressive therapy. A prospective study in 305 patients. Hepato-gastroenterology 1999;46:2925-2930.
31. FONG TL, VALINLUCK B, GOVINDARAJAN S, CHARBONEAU F, ADKINS RH, REDEKER AG. Short-term prednisone therapy affects aminotransferase activity and hepatitis C virus RNA level in chronic hepatitis C. Gastroenterology 1994;107:196-199.
32. ZUCKERMAN E, ZUCKERMAN T, DOUER D, QIAN D, LEVINE AM. Liver dysfunction in patients infected with hepatitis C virus undergoing chemotherapy for hematologic malignancies. Cancer 1998;83:1224-1230.
33. FAN FS, TZENG CH, HSIAO KI, HU ST, LIU WT, CHEN PM. Withdrawal of immunosuppressive therapy in allogenic bone marrow transplantation reactivates chronic viral hepatitis C. Bone Marrow Transpl 1991;8:417-420.
34. GRUBER A, LUNDBERG LG, BJORKHOLM M. Reactivation of chronic hepatitis C after withdrawal of immunosuppressive therapy. J Int Med 1993;234:223-225.
35. VENTO S, CAINELLI F, MIRANDOLA F, Cosco L, DI PERRI G, SOLBIATI M, FERRARO T, CONCIA E. Fulminant hepatitis on withdrawal of chemotherapy in carriers of hepatitis C virus. Lancet 1996;347:92-93.